METHODS: Patients aged < 18 years with abdominopelvic tumours who underwent either CEUS-GB or US-GB between April 2005 and May 2022 were retrospectively evaluated. Tumours diagnosed as malignancies by pathology were considered true-positive findings. Benign lesions were identified by pathology or clinical follow-up of at least 6 months. The diagnostic performance of the two groups was compared using propensity score matching (PSM). Complications were also analysed.
RESULTS: The present study included 764 paediatric patients (437 boys; median age, 24 months; interquartile range, 10-60 months); 151 were in the CEUS-GB group, and 613 were in the US-GB group. The sample adequacy rate was 100% (151 of 151) for the CEUS-GB group, which was greater than the 97.4% (597 of 613) for the US-GB group (p < 0.001). The overall diagnostic accuracy of the CEUS-GB group and US-GB group was 98.7% (149 of 151) versus 97.3% (581 of 597) in the total cohort (p = 0.551) and 98.7% (149 of 151) versus 92.7% (140 of 151) in the PSM cohort (p = 0.020). Two patients (0.3%) in the US-GB group experienced complications (Common Terminology Criteria for Adverse Events (CTCAE), grade 1-2) correlated with the biopsy. No adverse reactions occurred in the CEUS-GB group.
CONCLUSIONS: CEUS-GB of abdominopelvic tumours in paediatric patients is an effective and safe procedure with greater diagnostic accuracy than US-GB, especially for tumours with necrotic areas.
CONCLUSIONS: Contrast-enhanced US-guided biopsy of solid abdominal and pelvic tumours in paediatric patients is an effective and safe procedure with greater diagnostic accuracy than US-guided biopsy, especially for tumours with necrotic areas.
CONCLUSIONS: Contrast-enhanced ultrasound (CEUS) may be superior to conventional ultrasound at guiding biopsy of abdominopelvic masses in paediatric patients. CEUS-guided core needle biopsy of abdominopelvic masses in children was safe and resulted in a diagnostic yield of 98.7%. CEUS guidance should be considered in this population when colour Doppler US is unable to determine a biopsy site.
方法:在2005年4月至2022年5月期间接受CEUS-GB或US-GB治疗的年龄<18岁的腹盆腔肿瘤患者进行回顾性评估。通过病理学诊断为恶性肿瘤的肿瘤被认为是真阳性结果。通过病理或至少6个月的临床随访确定良性病变。使用倾向评分匹配(PSM)比较两组的诊断性能。并发症也进行了分析。
结果:本研究包括764名儿科患者(437名男孩;中位年龄,24个月;四分位数范围,10-60个月);CEUS-GB组151人,613人属于US-GB组。CEUS-GB组的样本充足率为100%(151/151),高于US-GB组的97.4%(613个中的597个)(p<0.001)。CEUS-GB组和US-GB组的总诊断准确率分别为98.7%(151个中的149个)和97.3%(581个中的597个)(p=0.551),PSM组(p=0.020)分别为98.7%(151个中的149个)和92.7%(151个中的140个)。US-GB组中有两名患者(0.3%)出现并发症(不良事件通用术语标准(CTCAE),1-2级)与活检相关。CEUS-GB组无不良反应发生。
结论:CEUS-GB用于儿科患者腹肾盂肿瘤是一种有效且安全的方法,诊断准确性高于US-GB,特别是对于有坏死区域的肿瘤。
结论:小儿腹部和盆腔实性肿瘤的超声引导活检是一种有效且安全的方法,诊断准确性高于超声引导活检。特别是对于有坏死区域的肿瘤。
结论:超声造影(CEUS)在指导小儿腹盆腔肿块活检方面可能优于常规超声。CEUS引导下对儿童腹盆腔肿块进行芯针活检是安全的,诊断率为98.7%。当彩色多普勒超声无法确定活检部位时,应在该人群中考虑超声造影指导。